D. Boral Capital analyst Jason Kolbert lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $8 from $15 and keeps a Buy rating on the shares following the Q4 report. The firm cites the “depressed valuation” of the stock and the company’s need for capital for the target cut. However, it still believes in the therapeutic potential of brilaroxazine.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH: